These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 35392088)

  • 1. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
    Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
    Front Immunol; 2022; 13():831636. PubMed ID: 35392088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathway.
    Wang Y; Zhang S; Zhao Z; Jin Q; Wang Z; Song Z; Liu L; Zhao Z
    Immunobiology; 2024 May; 229(3):152802. PubMed ID: 38569452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
    Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
    Front Immunol; 2021; 12():774103. PubMed ID: 35250965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic and Antiproliferative Effects of β-Mangostin on Rat C6 Glioma Cells Depend on Oxidative Stress Induction via PI3K/AKT/mTOR Pathway Inhibition.
    Li K; Wu L; Chen Y; Li Y; Wang Q; Li M; Hao K; Zhang W; Jiang S; Wang Z
    Drug Des Devel Ther; 2020; 14():5315-5324. PubMed ID: 33293793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling.
    Wang B; Zhang X; Li ZS; Wei C; Yu RZ; Du XZ; He YJ; Ren Y; Zhen YW; Han L
    Cancer Lett; 2024 Mar; 585():216665. PubMed ID: 38290657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas.
    Zhu Y; Zhang X; Qi L; Cai Y; Yang P; Xuan G; Jiang Y
    Oncotarget; 2016 Mar; 7(12):14429-40. PubMed ID: 26894862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway.
    Gao X; Jiang W; Ke Z; Huang Q; Chen L; Zhang G; Li C; Yu X
    Biochem Biophys Res Commun; 2022 Jan; 586():34-41. PubMed ID: 34826698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.
    Wang B; Cao C; Liu X; He X; Zhuang H; Wang D; Chen B
    Cell Oncol (Dordr); 2020 Apr; 43(2):223-235. PubMed ID: 31776938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
    Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
    Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.
    Tu M; Wange W; Cai L; Zhu P; Gao Z; Zheng W
    Tumour Biol; 2016 Nov; 37(11):14701-14709. PubMed ID: 27623944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genomic, transcriptomic, and epigenetic analyses identify a leukotriene synthesis-related M2 macrophage gene signature that predicts prognosis and treatment vulnerability in gliomas.
    Ji H; Liu Z; Wang N; Jin J; Zhang J; Dong J; Wang F; Yan X; Gong Q; Zhao H; Sun H; Li Y; Hu S; You C
    Front Immunol; 2022; 13():970702. PubMed ID: 36159811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remodeling cancer stemness by collagen/fibronectin
    Zhong C; Tao B; Tang F; Yang X; Peng T; You J; Xia K; Xia X; Chen L; Peng L
    Theranostics; 2021; 11(4):1991-2005. PubMed ID: 33408794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.